# Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD

> **NCT07634367** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- COPD (Chronic Obstructive Pulmonary Disease)

## Interventions

- **DRUG:** HSK39004 Inhalation Suspension

## Key facts

- **NCT ID:** NCT07634367
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2027-12-24
- **Final completion:** 2027-12-24
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634367, "Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07634367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*